EPIAO

Grade: Pharmaceutical Grade

Factory Location: Shenyang Liaoning China

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Erythropoietin is a glycoprotein that excreted in the kidney and stimulates the proliferation and differentiation of committed erythroid progenitors in the bone marrow. It can increase the production of Red Blood Cells.

Indications: Anemia associated with renal failure: including patients on hemodialysis (HD) and non-dialysis (ND), peri-operative red blood cell mobilization, and anemia associated with chemotherapy in cancer patients with non-myeloid malignancies. EPIAO is firstly approved for the treatment of peri-operative red blood cell mobilization and anemia associated with chemotherapy in cancer patients in China.

10,000IU/vial is the unique specification developed by 3SBio, which could be used conveniently in all above-mentioned indications. In 2011, the SFDA approved a 36,000 IU formulation for chemotherapy indications